New approach works on virulent TB type
Patients afflicted with multi-drug-resistant tuberculosis – 170,000 of whom died in 2013 of this untreatable (at least with antibiotics) form – may take hope from new research reported in Lancet this month.
New studies are investigating a novel therapy using infusions of autologous mesenchymal stromal cells (AMSC) to improve immune response against this virulent strain. The new therapy is actually working for many patients.